KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $98.7 million.

  • West Pharmaceutical Services' Non-Current Deferred Tax Liability rose 1177.8% to $98.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $98.7 million, marking a year-over-year increase of 1177.8%. This contributed to the annual value of $98.7 million for FY2025, which is 1177.8% up from last year.
  • West Pharmaceutical Services' Non-Current Deferred Tax Liability amounted to $98.7 million in Q4 2025, which was up 1177.8% from $22.8 million recorded in Q3 2025.
  • West Pharmaceutical Services' Non-Current Deferred Tax Liability's 5-year high stood at $98.7 million during Q4 2025, with a 5-year trough of $1.2 million in Q2 2022.
  • For the 5-year period, West Pharmaceutical Services' Non-Current Deferred Tax Liability averaged around $30.3 million, with its median value being $16.0 million (2023).
  • Per our database at Business Quant, West Pharmaceutical Services' Non-Current Deferred Tax Liability plummeted by 9016.39% in 2022 and then skyrocketed by 118333.33% in 2023.
  • Over the past 5 years, West Pharmaceutical Services' Non-Current Deferred Tax Liability (Quarter) stood at $48.6 million in 2021, then soared by 63.37% to $79.4 million in 2022, then grew by 7.3% to $85.2 million in 2023, then grew by 3.64% to $88.3 million in 2024, then grew by 11.78% to $98.7 million in 2025.
  • Its Non-Current Deferred Tax Liability was $98.7 million in Q4 2025, compared to $22.8 million in Q3 2025 and $23.0 million in Q2 2025.